INVO Fertility, Inc (NASDAQ:IVF) Short Interest Up 60.9% in August

INVO Fertility, Inc (NASDAQ:IVF) saw a significant increase in short interest during the month of August. As of August 31st, there was short interest totaling 367,548 shares, an increase of 60.9% from the August 15th total of 228,460 shares. Currently, 14.7% of the shares of the company are sold short. Based on an average daily volume of 11,714,828 shares, the days-to-cover ratio is presently 0.0 days.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Wall Street Zen upgraded INVO Fertility to a “hold” rating in a research note on Saturday, August 29th. Weiss Ratings restated a “sell (e+)” rating on shares of INVO Fertility in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

INVO Fertility Stock Performance

IVF stock traded down $0.00 during trading on Thursday, reaching $0.93. 76,140 shares of the stock were exchanged, compared to its average volume of 2,092,177. INVO Fertility has a twelve month low of $0.90 and a twelve month high of $84.40. The company has a current ratio of 0.71, a quick ratio of 0.67 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $2.33 million, a P/E ratio of -0.03 and a beta of 2.34. The stock has a 50 day simple moving average of $1.04 and a 200-day simple moving average of $1.84.

INVO Fertility (NASDAQ:IVF) last posted its quarterly earnings results on Friday, August 14th. The company reported $0.35 EPS for the quarter. INVO Fertility had a negative return on equity of 85.54% and a negative net margin of 116.29%.The firm had revenue of $2.18 million during the quarter.

INVO Fertility Company Profile

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.